[{"id":"efbc0b1e-49fe-45ea-b62f-1440004dacbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01086267","created_at":"2021-01-18T04:17:00.998Z","updated_at":"2024-07-02T16:37:31.020Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01086267","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • BMS-908662"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 08/01/2011","study_completion_date":" 08/01/2011","last_update_posted":"2016-06-27"}]